CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The investigators are interested in determining if there is a meaningful benefit from the use
of medications purported to increase the pumping function of the heart (i.e. inotropes) among
critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the
investigators will conduct a multi-centre, double blind, randomized control trial with
patients who are deemed to require these medications by their treating physician to one of
the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each
patient will be closely monitored by their healthcare team. The dose of medication will be
adjusted according to each patients' clinical status. After 12 hours, the participants will
move to open label treatment and any continued use of inotropes will be at the discretion of
their treating physician.